secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001140361-24-036399
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Biologics Q2 revenue $107.2M (+78% YoY); raises FY2024 revenue guidance to >$400M
--------------------------------------------------------------------------------

- Q2 2024 total revenue $107.2M, up 78% YoY; GAAP net income $32.1M vs loss of $6.4M a year ago.
- Adjusted EBITDA $44.5M, up ~592% YoY; gross margin improved to 53.6% from 27.8%.
- FY2024 revenue guidance raised to >$400M (from >$355M); FY2025 revenue >$445M (from >$410M).
- FY2024 GAAP net income guidance raised to >$105M; adjusted EBITDA guidance >$150M.
- Commercial-scale yield enhancement of ~20% from same starting plasma; potential benefit as early as Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036124036399/0001140361-24-036399-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036124036399/ef20033774_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-036399

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer